Study Comparing PEG 3350 Laxative to Placebo in the Treatment of Occasional Constipation (Study CL2007-12)(P08216)

NCT00770432 | Completed Phase 4 Results

• 3 other identifiers: 18130CL2007-12P08216
• Study Type: interventional
• Target: 203
• Locations: 0 countries
• Sites: N/A

Brief Summary

Randomized, placebo-controlled, double blind study. 203 subjects entered the study to compare the effect on occasional constipation of polyethylene glycol 3350 to placebo. Subjects took one of study treatments up to 7 days.

Conditions

Constipation

Keywords

Human Experimentation

Outcome Measures

Primary Outcomes (1)

• Number of Participants With a Complete Resolution at the Final Visit

  A resolution was recorded if the participant has no occurrence of two or more consecutive unsuccessful bowel movements for the rest of the study following the first successful bowel movement.

  24 hours to 3 days after last dose of seven day treatment period.

Study Arms (2)

Polyethylene glycol 3350 powder for solution

ACTIVE COMPARATOR

MiraLAX® (polyethylene glycol 3350 powder for solution)

Drug: Polyethylene glycol 3350

Placebo

PLACEBO COMPARATOR

MALTRIN 500® M500 (maltodextrin 500)

Other: Placebo, maltodextrin 500 powder for solution

Interventions

Polyethylene glycol 3350 DRUG

Polyethylene glycol 3350 powder for solution. Single dose (17 grams in 4 to 8 ounces of beverage) for 7 days.

Also known as: MiraLAX®

Polyethylene glycol 3350 powder for solution

Placebo, maltodextrin 500 powder for solution OTHER

Maltodextrin 500 powder for solution, One single dose (one capful) in any 4 - 8 ounces beverage for 7 days.

Also known as: MALTRIN® 500 powder for solution

Placebo

Eligibility Criteria

• Age: 17 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• Subjects (or parents/guardians of minors) must demonstrate their willingness to participate (or to have their children/wards participate) in the study and comply with its procedures by signing a written informed consent. Minor subjects must provide written assent.
• Subjects must be 17 years of age or older.
• Subjects must present with a current diagnosis of untreated constipation for 7 days or less based on having signs/symptoms of straining and hard or lumpy stools OR the inability to have a BM within 48 hours prior to randomization into the trial.
• Subjects must be OTC laxative users for the treatment of occasional constipation (defined as using a nonprescription laxative to treat at least 3 episodes of constipation within the last 12 months prior to randomization).
• Subjects must be willing to use study drug for up to 7 days as directed, and must agree to record bowel movement (frequency, consistency, etc.) accurately and consistently in a daily diary, and make two clinic visits.
• Subjects must be otherwise in good health, as determined by physical exam and medical history.
• Subjects must agree not to use any other products to treat their constipation during the course of the study.
• Subjects must agree not to use any medication known to cause constipation during the course of the study.
• Subjects must agree to maintain a similar diet from the week prior to randomization through end of study.
• Female subjects must be either surgically sterile, 2 years post-menopausal, or they attest that they are using an acceptable method of contraception (including hormonal birth control, IUD, double barrier methods, or vasectomized partner). In females of childbearing potential, the urine pregnancy test (HCG) must be negative at Baseline.
• Subjects must be able to read the diaries in English.

You may not qualify if:

• Subjects currently under a doctor's care and treatment for constipation.
• Subjects having current constipation episode for more than one week prior to randomization.
• Subjects that have a history of chronic constipation due to any underlying cause (inflammatory bowel disease, etc.).
• Subjects have a history of more than 3 months of constipation in the past year.
• Subjects have severe abdominal pain as the predominant constipation symptom.
• Subjects who have previously used a polyethylene glycol laxative.
• Subjects who have celiac disease or known gluten sensitivity.
• Subjects who have a history of colorectal cancer, anal abscess, anal fistula, anal fissure, anal stenosis, gastric retention or obstruction, bowel resection, rectocele, or colostomy.
• Subjects with known renal or hepatic insufficiency.
• Subjects with gastrointestinal bleeding or acute infection.
• Subjects with a history of alcohol or drug abuse.
• Subjects with a history of psychiatric disorders.
• Subjects with a history of significant ongoing medical problems, including kidney disease, or who are scheduled for surgical procedures.
• Subjects currently taking or taken within 7 days of randomization a concomitant medication that causes constipation including for example opiates, antidepressants, SSRI's, antimotility agents, and anticholinergics, etc.
• Subjects who plan to use laxatives during the treatment period other than the study medication.

Sponsors & Collaborators

• Bayer: lead

Related Publications (1)

• McGraw T. Polyethylene glycol 3350 in occasional constipation: A one-week, randomized, placebo-controlled, double-blind trial. World J Gastrointest Pharmacol Ther. 2016 May 6;7(2):274-82. doi: 10.4292/wjgpt.v7.i2.274.

  PMID: 27158544 DERIVED

MeSH Terms

Conditions

Constipation

Interventions

polyethylene glycol 3350; Solutions

Condition Hierarchy (Ancestors)

Signs and Symptoms, Digestive; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Pharmaceutical Preparations

Results Point of Contact

• Title: Therapeutic Area Head
• Organization: BAYER

clinical-trials-contact@bayer.com

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: OTHER
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 4
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 9, 2008
• First Posted: October 10, 2008
• Study Start: November 1, 2007
• Primary Completion: January 1, 2008
• Study Completion: January 1, 2008
• Last Updated: October 2, 2018
• Results First Posted: August 12, 2009

Record last verified: 2018-09